Inhibition of Skp2 enhances doxorubicin-induced cell death in B cell precursor acute lymphoblastic leukemia.
Skp2
acute lymphoblastic leukemia
cell cycle
cell death
chemosensitivity
Journal
Cell biology international
ISSN: 1095-8355
Titre abrégé: Cell Biol Int
Pays: England
ID NLM: 9307129
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
21
01
2022
received:
15
09
2021
accepted:
06
02
2022
pubmed:
11
2
2022
medline:
7
6
2022
entrez:
10
2
2022
Statut:
ppublish
Résumé
S-phase kinase-associated protein 2 (Skp2) is a well-defined component of the Skp2-Culin1-F-box (SCF) E3 ubiquitin ligase complex, which is involved in cell cycle progression and considered a prognostic marker in cancers. Overexpression of Skp2 is frequently observed in patients with acute lymphoblastic leukemia (ALL). Inhibition of this protein may be a valuable strategy to induce apoptosis in malignant cells. Less well known is the effect of Skp2 inhibition on the potentiation of the chemotherapeutic-induced cell death in B cell precursor acute lymphoblastic leukemia (BCP-ALL). Our results demonstrated that inhibition of the Skp2 using SZL P1-41, not only resulted in caspase-mediated apoptosis but also potentiated doxorubicin-induced apoptosis in BCP-ALL cell lines (NALM-6 and SUP-B15). SZL P1-41 in combination with doxorubicin altered cell cycle distribution and the level of cyclins and cyclin-dependent kinases in BCP-ALL cells. DNA damage response genes were also upregulated in presence of the doxorubicin and SZL P1-41 in both cell lines. In conclusion, our results indicated that inhibition of Skp2 either alone or in a combination with doxorubicin may hold promise in the future treatment of BCP-ALL.
Substances chimiques
S-Phase Kinase-Associated Proteins
0
Cyclin-Dependent Kinase Inhibitor p27
147604-94-2
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
895-906Subventions
Organisme : Iran University of Medical Sciences
ID : 14681
Informations de copyright
© 2022 International Federation for Cell Biology.
Références
Aguiló, N., Uranga, S., Marinova, D., Martín, C., & Pardo, J. (2014). Bim is a crucial regulator of apoptosis induced by Mycobacterium tuberculosis. Cell Death & Disease, 5(7), e1343. https://doi.org/10.1038/cddis.2014.313
Anaya-Eugenio, G. D., Tan, C. Y., Rakotondraibe, L. H., & de Blanco, E. C. C. (2020). Tumor suppressor p53 independent apoptosis in HT-29 cells by auransterol from Penicillium aurantiacobrunneum. Biomedicine & Pharmacotherapy, 127, 110124. https://doi.org/10.1016/j.biopha.2020.110124
Andreu, E. J., Lledó, E., Poch, E., Ivorra, C., Albero, M. P., Martínez-Climent, J. A., Montiel-Duarte, C., Rifón, J., Pérez-Calvo, J., Arbona, C., Prósper, F., & Pérez-Roger, I. (2005). BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Research, 65(8), 3264-3272. https://doi.org/10.1158/0008-5472.CAN-04-1357
Asmamaw, M. D., Liu, Y., Zheng, Y. C., Shi, X. J., & Liu, H. M. (2020). Skp2 in the ubiquitin-proteasome system: A comprehensive review. Medicinal Research Reviews, 40(5), 1920-1949. https://doi.org/10.1002/med.21675
Bretones, G., Acosta, J. C., Caraballo, J. M., Ferrándiz, N., Gómez-Casares, M. T., Albajar, M., Blanco, R., Ruiz, P., Hung, W. C., Albero, M. P., Perez-Roger, I., & León, J. (2011). SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27KIP1 through SKP2 in human leukemia cells. Journal of Biological Chemistry, 286(11), 9815-9825. https://doi.org/10.1074/jbc.M110.165977
Chen, J. (2016). The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harbor Perspectives in Medicine, 6(3), a026104. https://doi.org/10.1101/cshperspect.a026104
Chen J.-Y., Wang M.-C., & Hung W.-C. (2009). Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells. Leukemia Research, 33(11), 1520-1524. http://doi.org/10.1016/j.leukres.2009.03.007
Chen, J. Y., Wang, M. C., & Hung, W. C. (2011). Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. Journal of Cellular Physiology, 226(2), 407-413. https://doi.org/10.1002/jcp.22346
Chen, Q., Xie, W., Kuhn, D. J., Voorhees, P. M., Lopez-Girona, A., Mendy, D., & Moutouh-de Parseval, L. (2008). Targeting the p27 E3 ligase SCFSkp2 results in p27-and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood, The Journal of the American Society of Hematology, 111(9), 4690-4699. https://doi.org/10.1182/blood-2007-09-112904
Davidovich, S., Ben-Izhak, O., Shapira, M. A., Futerman, B., & Hershko, D. D. (2008). Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast Cancer Research, 10(4), 1-10. https://doi.org/10.1186/bcr2122
Dohda, T., Maljukova, A., Liu, L., Heyman, M., Grandér, D., Brodin, D., Sangfelt, O., & Lendahl, U. (2007). Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. Experimental Cell Research, 313(14), 3141-3152. https://doi.org/10.1016/j.yexcr.2007.04.027
Frescas, D., & Pagano, M. (2008). Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: Tipping the scales of cancer. Nature Reviews Cancer, 8(6), 438-449. https://doi.org/10.1038/nrc2396
Gaudichon, J., Jakobczyk, H., Debaize, L., Cousin, E., Galibert, M.-D., Troadec, M.-B., & Gandemer, V. (2019). Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: reconciling biological concepts and clinical issues. Blood Reviews, 36, 40-56. https://doi.org/10.1016/j.blre.2019.04.003
Greaves, M. (2018). A causal mechanism for childhood acute lymphoblastic leukaemia. Nature Reviews Cancer, 18(8), 471-484. https://doi.org/10.1038/s41568-018-0015-6
Jekimovs, C., Bolderson, E., Suraweera, A., Adams, M., O'Byrne, K. J., & Richard, D. J. (2014). Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: The good, the bad, and the promising. Frontiers in Oncology, 4, 86. https://doi.org/10.3389/fonc.2014.00086
Kamran, S., Sinniah, A., Alshawsh, M. A., Kamran S., Sinniah A., & Alshawsh M. A. (2021). Synergistic Effects of 5-Fluorouracil in Combination with Diosmetin in Colorectal Cancer Cells. Biology and Life Sciences Forum, 7(1), 6. http://doi.org/10.3390/ecb2021-10276
Kim, S. Y., Herbst, A., Tworkowski, K. A., Salghetti, S. E., & Tansey, W. P. (2003). Skp2 regulates Myc protein stability and activity. Molecular Cell, 11(5), 1177-1188. https://doi.org/10.1016/S1097-2765(03)00173-4
Kulinski, M., Achkar, I. W., Haris, M., Dermime, S., Mohammad, R. M., & Uddin, S. (2018). Dysregulated expression of SKP2 and its role in hematological malignancies. Leukemia & Lymphoma, 59(5), 1051-1063. https://doi.org/10.1080/10428194.2017.1359740
Lee, Y., & Lim, H.-S. (2016). Skp2 inhibitors: Novel anticancer strategies. Current Medicinal Chemistry, 23(22), 2363-2379.
Von Der Lehr, N., Johansson, S., Wu, S., Bahram, F., Castell, A., Cetinkaya, C., Hydbring, P., Weidung, I., Nakayama, K., Nakayama, K. I., Söderberg, O., Kerppola, T. K., & Larsson, L. G. (2003). The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Molecular Cell, 11(5), 1189-1200. https://doi.org/10.1016/S1097-2765(03)00193-X
Li, X., Bian, Y., Takizawa, Y., Hashimoto, T., Ikoma, T., Tanaka, J., Kitamura, N., Inagaki, Y., Komada, M., & Tanaka, T. (2013). ERK-dependent downregulation of Skp2 reduces Myc activity with HGF, leading to inhibition of cell proliferation through a decrease in Id1 expression. Molecular Cancer Research, 11(11), 1437-1447. https://doi.org/10.1158/1541-7786.MCR-12-0718
Lim, S., & Kaldis, P. (2013). Cdks, cyclins and CKIs: Roles beyond cell cycle regulation. Development, 140(15), 3079-3093. https://doi.org/10.1242/dev.091744
Mullan, P., Quinn, J., & Harkin, D. (2006). The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene, 25(43), 5854-5863. https://doi.org/10.1038/sj.onc.1209872
Nakayama, K., Nagahama, H., Minamishima, Y. A., Matsumoto, M., Nakamichi, I., Kitagawa, K., Shirane, M., Tsunematsu, R., Tsukiyama, T., Ishida, N., Kitagawa, M., Nakayama, K., & Hatakeyama, S. (2000). Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication. The EMBO Journal, 19(9), 2069-2081. https://doi.org/10.1093/emboj/19.9.2069
Nakayama, K., Nagahama, H., Minamishima, Y. A., Miyake, S., Ishida, N., Hatakeyama, S., Kitagawa, M., Iemura, S., Natsume, T., & Nakayama, K. I. (2004). Skp2-mediated degradation of p27 regulates progression into mitosis. Developmental Cell, 6(5), 661-672. https://doi.org/10.1016/S1534-5807(04)00131-5
Peng, M., Li, H., Luo, Z., Kong, J., Wan, Y., Zheng, L., Zhang, Q., Niu, H., Vermorken, A., Van de Ven, W., Chen, C., Zhang, X., Li, F., Guo, L., & Cui, Y. (2015). Dextran-coated superparamagnetic nanoparticles as potential cancer drug carriers in vivo. Nanoscale, 7(25), 11155-11162. https://doi.org/10.1039/C5NR01382H
Pratheeshkumar, P., Siraj, A. K., Divya, S. P., Parvathareddy, S. K., Begum, R., Melosantos, R., Al-Sobhi, S. S., Al-Dawish, M., Al-Dayel, F., & Al-Kuraya, K. S. (2018). Downregulation of SKP2 in papillary thyroid cancer acts synergistically with TRAIL on inducing apoptosis via ROS. The Journal of Clinical Endocrinology & Metabolism, 103(4), 1530-1544. https://doi.org/10.1210/jc.2017-02178
Pui C-H., & Evans W. E. (2006). Treatment of acute lymphoblastic leukemia. New England Journal of Medicine, 354(2), 166-178. http://doi.org/10.1056/nejmra052603
Radke, S., Pirkmaier, A., & Germain, D. (2005). Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene, 24(21), 3448-3458. https://doi.org/10.1038/sj.onc.1208328
Ren, D., Tu, H.-C., Kim, H., Wang, G. X., Bean, G. R., Takeuchi, O., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J., & Cheng, E. H. (2010). BID, BIM, and PUMA are essential for activation of the BAX-and BAK-dependent cell death program. Science, 330(6009), 1390-1393. https://doi.org/10.1126/science.1190217
Rose, A. E., Wang, G., Hanniford, D., Monni, S., Tu, T., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Pagano, M., Darvishian, F., Mazumdar, M., Hernando, E., & Osman, I. (2011). Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell & Melanoma Research, 24(1), 197-206. https://doi.org/10.1111/j.1755-148X.2010.00784.x
Roy, A., & Banerjee, S. (2015). p27 and leukemia: cell cycle and beyond. Journal of Cellular Physiology, 230(3), 504-509. https://doi.org/10.1002/jcp.24819
Saralamma, V. V., Nagappan, A., Hong, G. E., Lee, H. J., Yumnam, S., Raha, S., Heo, J. D., Lee, S. J., Lee, W. S., Kim, E. H., & Kim, G. S. (2015). Poncirin induces apoptosis in AGS human gastric cancer cells through extrinsic apoptotic pathway by up-regulation of fas ligand. International Journal of Molecular Sciences, 16(9), 22676-22691. https://doi.org/10.3390/ijms160922676
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., Soulier, J., Chen-Kiang, S., & Aifantis, I. (2012). Therapeutic targeting of the cyclin D3: CDK4/6 complex in T cell leukemia. Cancer Cell, 22(4), 452-465. https://doi.org/10.1016/j.ccr.2012.09.016
Seki, R., Okamura, T., Koga, H., Yakushiji, K., Hashiguchi, M., Yoshimoto, K., Ogata, H., Imamura, R., Nakashima, Y., Kage, M., Ueno, T., & Sata, M. (2003). Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. American Journal of Hematology, 73(4), 230-235. https://doi.org/10.1002/ajh.10379
Terwilliger, T., & Abdul-Hay, M. (2017). Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer Journal, 7(6), e577. https://doi.org/10.1038/bcj.2017.53
Uddin, S., Hussain, A., Ahmed, M., Belgaumi, A., Al-Dayel, F., Ajarim, D., Bavi, P., & Al-Kuraya, K. S. (2008). S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 216(4), 483-494. https://doi.org/10.1002/path.2433
Wajant, H. (2002). The Fas signaling pathway: More than a paradigm. Science, 296(5573), 1635-1636. https://doi.org/10.1126/science.1071553
Wang, Z., Gao, D., Fukushima, H., Inuzuka, H., Liu, P., Wan, L., Sarkar, F. H., & Wei, W. (2012). Skp2: A novel potential therapeutic target for prostate cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1825(1), 11-17. https://doi.org/10.1016/j.bbcan.2011.09.002
Wu, J., Zhang, X., Zhang, L., Wu, C.-Y., Rezaeian, A. H., Chan, C.-H., Li, J. M., Wang, J., Gao, Y., Han, F., Jeong, Y. S., Yuan, X., Khanna, K. K., Jin, J., Zeng, Y. X., & Lin, H. K. (2012). Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1. Molecular Cell, 46(3), 351-361. https://doi.org/10.1016/j.molcel.2012.02.018
Wu, T., Gu, X., & Cui, H. (2021). Emerging roles of SKP2 in cancer drug resistance. Cells, 10(5), 1147. https://doi.org/10.3390/cells10051147
Xu, X., Huang, L., Zhang, Z., Tong, J., Mi, J., Wu, Y., Zhang, C., & Yan, H. (2019). Targeting non-oncogene ROS pathway by alantolactone in B cell acute lymphoblastic leukemia cells. Life Sciences, 227, 153-165. https://doi.org/10.1016/j.lfs.2019.04.034
Yang, C., Nan, H., Ma, J., Jiang, L., Guo, Q., Han, L., Zhang, Y., Nan, K., & Guo, H. (2015). High Skp2/low p57Kip2 expression is associated with poor prognosis in human breast carcinoma. Breast cancer: Basic and clinical research, 9, S30101-S30121. https://doi.org/10.4137/BCBCR.S30101
Zhang, W., Cao, L., Sun, Z., Xu, J., Tang, L., Chen, W., Luo, J., Yang, F., Wang, Y., & Guan, X. (2016). Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation. Cell Cycle, 15(10), 1344-1351. https://doi.org/10.1080/15384101.2016.1160986
Zhang, Y., Zvi, Y. S., Batko, B., Zaphiros, N., O'Donnell, E. F., Wang, J., & Koirala, P. (2018). Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. Scientific Reports, 8(1), 1-13. https://doi.org/10.1038/s41598-018-32428-9
Zheng, L., Dai, H., Zhou, M., Li, X., Liu, C., Guo, Z., Wu, X., Wu, J., Wang, C., Zhong, J., Huang, Q., Garcia-Aguilar, J., Pfeifer, G. P., & Shen, B. (2012). Polyploid cells rewire DNA damage response networks to overcome replication stress-induced barriers for tumour progression. Nature Communications, 3(1), 1-12. https://doi.org/10.1038/ncomms1825